Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm, Duke to Apply Metabolomics to Cardiovascular Drug Discovery

NEW YORK, Feb. 25 - Paradigm Genetics and researchers at the Duke University Medical Center have signed a multi-year research collaboration that seeks to apply metabolomics to drug discovery and development, Paradigm said on Monday.

Terms of the agreement call for Paradigm and the DUMC initially to research cardiovascular disease to identify and validate drug targets and to hunt for new biomarkers that may be used in predictive medicine. Studies are set to begin this quarter.

The research, which will extend beyond cardiovascular disease as the collaboration moves ahead, will bring together cardiology researchers at the university with Paradigm's metabolomics platform, MetaVantage.

"By bringing together [DUMC's] cardiologists with our ... experts in metabolomics, we believe we will identify new and better ways to diagnose and treat cardiovascular disease," John A. Ryals, Paradigm Genetics' president and CEO, said in a statement.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.